AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00194103 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Monitoring and Feedback
Description: In addition to attending IOP, participants receive phone contact from our counselors but only to receive a monitoring assessment. There is no feedback or counseling from study staff in this condition.
Study NCT02405260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: once daily
Study NCT02405260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study NCT04009590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Read educational booklet
Study NCT04009590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04009590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04009590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Utilize Quit4Health
Study NCT04035824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gastrodia and Uncaria granule
Description: Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.
Study NCT04035824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Gastrodia and Uncaria granule
Description: Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.
Study NCT00194103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Monitoring and Counseling
Description: In addition to attending IOP, participants have phone contact with study counselors, which includes monitoring, feedback, and counseling.
Study NCT01440530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
Study NCT01440530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
Study NCT00186927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sendai virus vaccine
Description: Enders strain; a live, unmodified intranasally administered Sendai virus vaccine; given once in a dose escalation study, 5 x 10\^5 to 5 x 10\^7 EID(50) units.
Study NCT03558100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obstacle crossing intervention for adults with obesity
Description: The obstacle crossing intervention will be done for reducing falls risks in obesity. The intervention will provide gait practice to individuals with obesity who are eligible for and prior to weight loss surgery.
Study NCT01784133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omiganan
Study NCT03119675 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GoCheck Kids (Windows)
Description: Photorefraction method is used to screen amblyopia risk factors.
Study NCT04500964 — intervention group
Intervention type: DEVICE
Intervention: TAVR
Description: Trancatheter aortic valve replacement
Study NCT00986128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 100 mg tablet twice daily for 3 weeks
Study NCT00986128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: One 100 mg and one 200 mg tablet twice daily for 3 weeks
Study NCT05262309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Pamrevlumab dosing, 30 mg/kg IV, will be administered at day 1, day 7 and day 14.~Based on Investigator's decision, treatment may be continued every 3 weeks after day 14, up to 11 weeks.
Study NCT02397122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet-rich fibrin
Description: autologous platelet-rich fibrin was isolated from venous blood of each patient by defined centrifugation methods
Study NCT02397122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: connective tissue graft was harvested from the palatal region of each patient by single incision method
Study NCT02397122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue graft
Description: connective tissue graft was harvested from the palatal region of each patient by single incision method
Study NCT02397122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap
Description: buccal gingival flap was raised by sharp-blunt-sharp dissection and positioned coronally to cover connective tissue graft (and platelet-rich fibrin gel)
Study NCT02397122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally advanced flap
Description: buccal gingival flap was raised by sharp-blunt-sharp dissection and positioned coronally to cover connective tissue graft (and platelet-rich fibrin gel)
Study NCT02675621 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phenolic Beverage
Study NCT02675621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phenolic Beverage
Study NCT01703247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Study NCT01703247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ganglionated plexi ablation
Study NCT01703247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Linear Lesion Ablation
Study NCT03994133 — intervention group
Intervention type: OTHER
Intervention: Measurement of the hydration state by bio-impedance spectroscopy
Description: * The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~* The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes.~* The measurement will be done in pre-dialytic
Study NCT04028895 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dosage of IRAP during OGTT
Description: Visit 1: oral glucose tolerance test. visit 2: hyperinsulinemic euglycemic clamp
Study NCT02107859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered per dose and schedule specified in the arm.
Study NCT01985607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: new extensively hydrolysed formula
Study NCT01985607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extensively hydrolysed formula
Study NCT00544115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: busulfan
Study NCT00544115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00544115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Study NCT00797979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skull Grip bone fixation
Description: Skull Grip bone fixation
Study NCT00797979 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sutures
Description: Standard skull bon flap fixation, sutures
Study NCT02877030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video game
Description: The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.
Study NCT02877030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video game
Description: The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.
Study NCT00817999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Description: Participants received grapefruit juice during 1 of the 2 periods.
Study NCT00817999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day
Study NCT00817999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg
Study NCT00777907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Description: 1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.
Study NCT00777907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coil embolization
Description: Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.
Study NCT00431184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentazocine
Description: see arms description
Study NCT00431184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: see arms description
Study NCT04382703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Affirmation Exercise
Description: The self affirming exercise is as follow:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines provided, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will .........................................~Options are as follows:~think about the things I value about myself, remember things that I have succeeded in, think about what I stand for or think about things that are important to me
Study NCT04382703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Given a questionnaire minus the self affirming exercise
Study NCT01621880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT01621880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
Study NCT00714376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 iv every 3 weeks for 8 cycles
Study NCT01337986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine/Placebo
Description: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
Study NCT01337986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo/Dalfampridine
Description: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.
Study NCT02081625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-065/NCNP-01
Description: NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:~Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks
Study NCT04077957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.
Study NCT04077957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine 2.25g per day will be the background therapy in participants in Group 1. Experimental.
Study NCT04077957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 0.2g per day will be the background therapy in participants in Group 1. Experimental.
Study NCT04077957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept (50mg per week, for 4 weeks)
Description: Participants in Group 1. Experimental who satisfied the criteria for high disease activity (ASDAS≥2.1) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 4 weeks.
Study NCT04077957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept (50mg per week, for 2 weeks)
Description: Participants in Group 1. Experimental who satisfied the criteria for low disease activity (2.1>ASDAS≥1.3) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 2 weeks.
Study NCT04077957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept (50mg per week)
Description: Participants in Group 2. Positive Control will receive etanercept (50mg per week, for 12 weeks) for 48 weeks.
Study NCT00632957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty acid (with SRP or OHI)
Description: 1000mg capsules three times daily, duration 28 weeks.
Study NCT00632957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: corn/soybean oil capsules 1g/three times daily
Study NCT01817374 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 2D US grayscale plus quantitative VCEUS
Description: This is a pilot study to evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy, comparing results with volume change on grayscale US and planar CEUS, and correlating imaging findings with pathological response on surgical specimens.
Study NCT04078737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor and Aspirin
Description: Day of randomization:~Day1:Ticagrelor 180mg; placebo of clopidogrel 300mg; aspirin 75-300mg (open label) Day2-21st: Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg; aspirin 75mg (open label) Day 22nd-3 months:Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg
Study NCT04078737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel and Aspirin
Description: Day of randomization:~Day 1: Clopidogrel 300mg; placebo of ticagrelor 180mg; aspirin 75-300mg (open label) Day2-21st: Clopidogrel 75mg/day; placebo of ticagrelor 90mg bid/day; aspirin 75mg (open label) Day 22nd-3 months:Clopidogrel 75mg; placebo of ticagrelor 90mg bid/day
Study NCT00106184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
Study NCT00106184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1
Study NCT02313909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15 mg, once daily, orally, tablet
Study NCT02313909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Description: 100 mg, once daily, orally, tablet
Study NCT00544115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Study NCT00544115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate
Study NCT02313909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rivaroxaban-Placebo
Description: Matching placebo, once daily, orally, tablet
Study NCT02313909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin-Placebo
Description: Matching placebo, once daily, orally, tablet
Study NCT03258424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428
Description: PTI-428 or placebo will be given QD for 14 days.
Study NCT03258424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PTI-428 or placebo will be given QD for 14 days.
Study NCT01583686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -5 to Day -1: Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
Study NCT01583686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)
Description: Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.
Study NCT01583686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study NCT01583686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Study NCT02871960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic and Laparoscopic Colectomy
Study NCT02871960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic and Laparoscopic Colectomy
Study NCT03659604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'SmartLife' with tailored feedback
Description: 'SmartLife' game with tailored feedback: mobile exergame with tailored feedback. Feedback will be based on accelerometer data from a sensor that is integrated in a T-shirt. The sensor captures individually calibrated accelerometer data and is paired with the mobile exergame. Depending on the physical activity intensity of the player, the game challenge and feedback adapts individually in real-time.
Study NCT03659604 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 'SmartLife' without tailored feedback
Description: 'SmartLife' without tailored feedback: mobile exergame without tailored feedback. The mobile exergame will not be paired to any sensor. The participant can play the mobile game, yet, will not receive any real-time feedback or adjustment in the game on physical activity intensity.
Study NCT03659604 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No game
Description: Passive control: School classes will be asked to continue their daily life as usual.
Study NCT01971164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951
Description: Subjects will receive JTZ-951 or Placebo
Study NCT01784133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02289768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/salicylic acid
Study NCT02289768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT03709082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 75mg
Description: Oral Administration
Study NCT03709082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Oral Adminstration
Study NCT03709082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Intravenous Administration
Study NCT03709082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 100mg
Description: Oral Administration
Study NCT03709082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Oral Administration
Study NCT03709082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Oral Administration
Study NCT03265899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU; 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
Study NCT03265899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray, 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
Study NCT01001169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)
Description: Two intramuscular injections
Study NCT00124020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: Telavancin 10 mg/kg/day IV for up to 21 days